Recently, the State Intellectual Property Office announced the list of national intellectual property demonstration enterprises and advantageous enterprises in 2022. Hihua Biotech was selected as a national intellectual property advantage enterprise.

The national intellectual property advantage enterprise is the highest honor and evaluation given by the state to the intellectual property management of the enterprise. The rated enterprises are all enterprises with certain influence and outstanding intellectual property advantages in the region.

The title is a national-level recognition in the field of intellectual property, which is evaluated by the State Intellectual Property Office in accordance with the requirements of the Notice of the Office of the State Intellectual Property Office on Carrying out the 2022 Demonstration Work for the Construction of an Intellectual Property Power for Enterprises, and integrates the performance of enterprises in technical capabilities, patent cultivation, application performance, transformation and efficiency, and intellectual property construction management.

Innovation is the number one driver of development. As a science and technology enterprise focusing on drug evaluation and technical services as well as biomedical research and development, Haihua Biotech attaches importance to the role of innovation in development, continuously strengthens investment in R&D and innovation, and strengthens the management and construction of intellectual property rights.

At present, the company has obtained more than 100 patents, soft writings, papers, etc., including more than 50 patent certificates, 1 US patent, and a number of invention patents are being accepted.